Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Chloroquine in IDH1/2-mutated Solid Tumors
NCT02496741Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Nov 2015
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) and chloroquine in glioma, intrahepatic cholangiocarcinoma (ICC) and chondrosarcoma, sponsored by University of Amsterdam. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Nov 2015; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)chloroquine
03
Conditions
gliomaintrahepatic cholangiocarcinoma (ICC)chondrosarcoma
Beyond the preview
Go deeper on NCT02496741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496741.